Physician profile
Edgar Olivas
NPI 1770902611
$5,292.42
in general payments reported to CMS, 2019-2025
34 companies · $728 in 2025
The $728 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2022: $816 · 2023: $840 · 2024: $1,132 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,637.63 | 2019 | |
| Ucb, INC. | $625.39 | 2022-2025 | Fintepla, Nayzilam, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $471.81 | 2022-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $456.35 | 2022-2025 | |
| Lilly USA, LLC | $266.23 | 2022-2025 | Amyvid, Emgality, Kisunla |
| Genentech USA, INC. | $253.07 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Lundbeck LLC | $180.98 | 2023-2025 | Vyepti |
| Sk Life Science, INC. | $163.66 | 2022-2025 | |
| Genentech, INC. | $138.55 | 2023-2024 | Ocrevus |
| Amneal Pharmaceuticals LLC | $136.29 | 2023-2025 | Rytary, Crexont |
| Eisai INC. | $129.56 | 2022-2024 | |
| Mdd US Operations, LLC | $113.02 | 2022-2025 | Gocovri, Gocovri |
| Kyowa Kirin, INC. | $71.76 | 2022-2024 | Nourianz |
| Upsher-Smith Laboratories LLC | $64.82 | 2022 | |
| Jazz Pharmaceuticals INC. | $63.10 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $55.73 | 2023 | Ampyra, Inbrija |
| Ani Pharmaceuticals, INC. | $44.18 | 2024 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $39.48 | 2022 | |
| Neurocrine Biosciences, INC. | $36.86 | 2024 | Ingrezza |
| Tanabe Pharma America, INC. | $28.68 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.44 | 2023 | Gammagard |
| Travere Therapeutics, INC. | $27.35 | 2022 | |
| Sumitomo Pharma America, INC. | $26.78 | 2023 | Aptiom |
| Alexion Pharmaceuticals, INC. | $26.34 | 2023 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $25.91 | 2023 | Fycompa |
| Amgen INC. | $24.72 | 2022 | |
| Celgene Corporation | $24.62 | 2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $24.14 | 2022 | |
| Ge Healthcare | $23.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.80 | 2023 | Wainua |
| Abbott Laboratories | $18.71 | 2025 | Infinity |
| Neurelis, INC. | $16.00 | 2025 | Valtoco |
| Penumbra, INC. | $15.13 | 2019 | |
| Nevro Corp. | $14.62 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Olivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.